Flash FinanceUS
Pre-market S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · Supernus Pharmaceuticals (SUPN)

Supernus agrees to all-stock merger of equals with Indivior; Q2 revenue up 32%

Mixed Impact 5 of 5 m&a Written later

Supernus reported second-quarter 2026 total revenues of $219.1 million, up 32% from a year earlier, and raised its full-year 2026 revenue guidance, but posted a net loss of $58.4 million after a $54.9 million non-cash impairment on APOKYN. The company also announced a definitive agreement to combine with Indivior Pharmaceuticals in an all-stock merger of equals, which would affect the ownership and business of Supernus shareholders.

Key points

  • Q2 2026 net loss of $58.4 million, or $1.01 per diluted share, versus net earnings of $22.5 million, or $0.40 per share, in Q2 2025
  • Full-year 2026 total revenue guidance raised to $860 million-$890 million from $840 million-$870 million; operating earnings guidance is now a loss of $20 million-$50 million, versus earnings of $0-$30 million previously
  • Adjusted operating earnings guidance raised to $150 million-$180 million from $140 million-$170 million
  • Merger exchange ratio is fixed; joint conference call with Indivior scheduled for August 3, 2026 at 8:30 a.m. EDT

The filing

CompanySupernus Pharmaceuticals (SUPN)
Form8-K, current report
Filed with the SECAug 3, 2026, 6:46 AM ET
Accession number0001356576-26-000035

Items reported: 2.02 Results of Operations

Read the filing on SEC.gov ↗

Written by AI on Nov 8, 2026, 6:57 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on August 03, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.